thiazoles has been researched along with 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cosimo, E; Leach, MT; McCaig, AM; Michie, AM | 1 |
1 trial(s) available for thiazoles and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
| Article | Year |
|---|---|
Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Benzoquinones; CD40 Ligand; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Interleukin-4; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Stromal Cells; Syk Kinase; Thiazoles; Time Factors | 2011 |